title: Probiotics, dendritic cells and bladder cancer.
abstract: What's known on the subject? and What does the study add? The suppressor effect of probiotics on superficial bladder cancer is an observed phenomenon but the specific mechanism is poorly understood. The evidence strongly suggests natural killer (NK) cells are the anti-tumour effector cells involved and NK cell activity correlates with the observed anti-tumour effect in mice. It is also known that dendritic cells (DC) cells are responsible for the recruitment and mobilization of NK cells so therefore it may be inferred that DC cells are most likely to be the interphase point at which probiotics act. In support of this, purification of NK cells was associated with a decrease in NK cells activity. The current use of intravesical bacille Calmette-Guérin in the management of superficial bladder cancer is based on the effect of a localised immune response. In the same way, understanding the mechanism of action of probiotics and the role of DC may potentially offer another avenue via which the immune system may be manipulated to resist bladder cancer. Probiotic foods have been available in the UK since 1996 with the arrival of the fermented milk drink (Yakult) from Japan. The presence of live bacterial ingredients (usually lactobacilli species) may confer health benefits when present in sufficient numbers. The role of probiotics in colo-rectal cancer may be related in part to the suppression of harmful colonic bacteria but other immune mechanisms are involved. Anti-cancer effects outside the colon were suggested by a Japanese report of altered rates of bladder tumour recurrence after ingestion of a particular probiotic. Dendritic cells play a central role to the general regulation of the immune response that may be modified by probiotics. The addition of probiotics to the diet may confer benefit by altering rates of bladder tumour recurrence and also alter the response to immune mechanisms involved with the application of intravesical treatments (bacille Calmette-Guérin).
authors.affiliation: Department of Urology, University College London Hospitals NHS Trust, London, UK.
authors.forename: Oladapo
authors.initials: O
authors.lastname: Feyisetan
authors.forename: Christopher
authors.initials: C
authors.lastname: Tracey
authors.forename: Giles O
authors.initials: GO
authors.lastname: Hellawell
mesh_terms: D000818:Animals; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007778:Lactobacillus; D019936:Probiotics / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy*